{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:46:44Z","timestamp":1763642804956,"version":"3.44.0"},"reference-count":45,"publisher":"BMJ","issue":"e1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2020,1,16]]},"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1136\/ejhpharm-2019-002060","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T17:15:49Z","timestamp":1581095749000},"page":"e41-e47","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness and safety of sofosbuvir\/velpatasvir \u00b1 ribavirin vs glecaprevir\/pibrentasvir in genotype 3 hepatitis C virus infected patients"],"prefix":"10.1136","volume":"27","author":[{"given":"Luis","family":"Margusino-Frami\u00f1\u00e1n","sequence":"first","affiliation":[{"name":"Pharmacy Service, Universitary Hospital of A Coru\u00f1a, A Coru\u00f1a, Spain"},{"name":"Division of Clinical Virology, Biomedical Research Institute of A Coru\u00f1a (INIBIC), Universitary Hospital of A Coru\u00f1a (CHUAC), Sergas, University of A Coru\u00f1a (UDC), A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purificaci\u00f3n","family":"Cid-Silva","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Universitary Hospital of A Coru\u00f1a, A Coru\u00f1a, Spain"},{"name":"Division of Clinical Virology, Biomedical Research Institute of A Coru\u00f1a (INIBIC), Universitary Hospital of A Coru\u00f1a (CHUAC), Sergas, University of A Coru\u00f1a (UDC), A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Rotea-Salvo","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Universitary Hospital of A Coru\u00f1a, A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Mena-de-Cea","sequence":"additional","affiliation":[{"name":"Division of Clinical Virology, Biomedical Research Institute of A Coru\u00f1a (INIBIC), Universitary Hospital of A Coru\u00f1a (CHUAC), Sergas, University of A Coru\u00f1a (UDC), A Coru\u00f1a, Spain"},{"name":"Infectious Diseases Unit. Internal Medicine Service, Universitary Hospital of A Coru\u00f1a (CHUAC), A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Su\u00e1rez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Hepatology Unit, Digestive System Service, University Hospital of A Coru\u00f1a (CHUAC), A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"V\u00e1zquez-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Division of Clinical Virology, Biomedical Research Institute of A Coru\u00f1a (INIBIC), Universitary Hospital of A Coru\u00f1a (CHUAC), Sergas, University of A Coru\u00f1a (UDC), A Coru\u00f1a, Spain"},{"name":"Infectious Diseases Unit. Internal Medicine Service, Universitary Hospital of A Coru\u00f1a (CHUAC), A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Delgado-Blanco","sequence":"additional","affiliation":[{"name":"Division of Clinical Virology, Biomedical Research Institute of A Coru\u00f1a (INIBIC), Universitary Hospital of A Coru\u00f1a (CHUAC), Sergas, University of A Coru\u00f1a (UDC), A Coru\u00f1a, Spain"},{"name":"Hepatology Unit, Digestive System Service, University Hospital of A Coru\u00f1a (CHUAC), A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Isabel","family":"Sanclaudio-Luhia","sequence":"additional","affiliation":[{"name":"Information Systems Department, University Hospital of A Coru\u00f1a, A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Mart\u00edn-Herranz","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Universitary Hospital of A Coru\u00f1a, A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngeles","family":"Castro-Iglesias","sequence":"additional","affiliation":[{"name":"Division of Clinical Virology, Biomedical Research Institute of A Coru\u00f1a (INIBIC), Universitary Hospital of A Coru\u00f1a (CHUAC), Sergas, University of A Coru\u00f1a (UDC), A Coru\u00f1a, Spain"},{"name":"Infectious Diseases Unit. Internal Medicine Service, Universitary Hospital of A Coru\u00f1a (CHUAC), A Coru\u00f1a, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"2025090704215336000_27.e1.e41.1","unstructured":"European Centre for Disease Prevention and Control . Hepatitis C-Annual epidemiological report for 2015, 2017. Available: https:\/\/ecdc.europa.eu\/en\/publications-data\/hepatitis-c-annual-epidemiological-report-2015 [Accessed 21 Sep 2019]."},{"key":"2025090704215336000_27.e1.e41.2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"2025090704215336000_27.e1.e41.3","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/jmv.21850","article-title":"Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France","volume":"82","author":"Larsen","year":"2010","journal-title":"J Med Virol"},{"key":"2025090704215336000_27.e1.e41.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.05.016"},{"key":"2025090704215336000_27.e1.e41.5","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.24432"},{"key":"2025090704215336000_27.e1.e41.6","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jhep.2009.08.001","article-title":"HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C","volume":"51","author":"De Nicola","year":"2009","journal-title":"J Hepatol"},{"key":"2025090704215336000_27.e1.e41.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01441.x"},{"key":"2025090704215336000_27.e1.e41.8","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.050302"},{"key":"2025090704215336000_27.e1.e41.9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.03.014"},{"key":"2025090704215336000_27.e1.e41.10","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.36370"},{"key":"2025090704215336000_27.e1.e41.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80166-X"},{"key":"2025090704215336000_27.e1.e41.12","article-title":"Direct-acting antivirals for chronic hepatitis C","volume":"9","author":"Jakobsen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090704215336000_27.e1.e41.13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1478-3231.2011.02703.x","article-title":"2011 European association of the study of the liver hepatitis C virus clinical practice guidelines","volume":"32(Suppl 1)","author":"Calvaruso","year":"2012","journal-title":"Liver Int"},{"key":"2025090704215336000_27.e1.e41.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.11.003"},{"key":"2025090704215336000_27.e1.e41.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"2025090704215336000_27.e1.e41.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"2025090704215336000_27.e1.e41.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"2025090704215336000_27.e1.e41.18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy585"},{"key":"2025090704215336000_27.e1.e41.19","first-page":"68","article-title":"Intelligent monitoring system for antiviral pharmacotherapy in patients with chronic hepatitis C (SiMON-VC)","volume":"41","author":"Margusino-Frami\u00f1\u00e1n","year":"2017","journal-title":"Farm Hosp"},{"key":"2025090704215336000_27.e1.e41.20","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad, Gobierno de Espa\u00f1a . INFORME de UTILIDAD TERAP\u00c9UTICA. UT\/V1\/28022012. Criterios Y recomendaciones generales para El tratamiento Con boceprevir Y telaprevir de la hepatitis cr\u00f3nica C (VHC) en pacientes monoinfectados. Available: https:\/\/www.mscbs.gob.es\/profesionales\/farmacia\/pdf\/TRATAMIENTO_HEPATITIS_CRONICA_C.pdf [Accessed 21 Sep 2019]."},{"key":"2025090704215336000_27.e1.e41.21","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12197"},{"key":"2025090704215336000_27.e1.e41.22","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H018"},{"key":"2025090704215336000_27.e1.e41.23","unstructured":"University of Liverpool . Hep drug interactions. Available: https:\/\/www.hep-druginteractions.org [Accessed 21 Sep 2019]."},{"key":"2025090704215336000_27.e1.e41.24","unstructured":"Up to Date . Lexicomp drug interactions. Available: https:\/\/www.uptodate.com\/home\/drugs-drug-interaction [Accessed 21 Sep 2019]."},{"key":"2025090704215336000_27.e1.e41.25","unstructured":"IBM Micromedex . Drug interactions. Available: https:\/\/www.micromedexsolutions.com\/micromedex2\/4.29.4.1\/WebHelp\/Tools\/Interactions\/Drug_Interactions.htm [Accessed 21 Sep 2019]."},{"key":"2025090704215336000_27.e1.e41.26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/cid\/cix260","article-title":"Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study","volume":"65","author":"Wyles","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025090704215336000_27.e1.e41.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"2025090704215336000_27.e1.e41.28","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/cid\/ciy220","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study","volume":"67","author":"Rockstroh","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025090704215336000_27.e1.e41.29","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(17)30326-4","article-title":"ENDURANCE-3: safety and efficacy of glecaprevir\/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-na\u00efve HCV genotype 3-infected patients without cirrhosis","volume":"66","author":"Foster","year":"2017","journal-title":"J Hepatol"},{"key":"2025090704215336000_27.e1.e41.30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29541"},{"key":"2025090704215336000_27.e1.e41.31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"2025090704215336000_27.e1.e41.32","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1002\/hep.29852","article-title":"Elbasvir\/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: a randomized trial","volume":"67","author":"Foster","year":"2018","journal-title":"Hepatology"},{"key":"2025090704215336000_27.e1.e41.33","unstructured":"European Medicines Agency . Committee for medicinal products for human use. Epclusa. Assessment report, 2017. Available: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/epclusa-epar-public-assessment-report_en.pdf [Accessed 21 Sep 2019]."},{"key":"2025090704215336000_27.e1.e41.34","unstructured":"European Medicines Agency . Committee for medicinal products for human use. Mavyret. Assessment report, 2016. Available: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/maviret-epar-public-assessment-report_en.pdf [Accessed 21 Sep 2019]."},{"key":"2025090704215336000_27.e1.e41.35","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s00535-017-1396-0","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection","volume":"53","author":"Kumada","year":"2018","journal-title":"J Gastroenterol"},{"key":"2025090704215336000_27.e1.e41.36","doi-asserted-by":"crossref","DOI":"10.1007\/s00535-017-1409-z","article-title":"Correction to: efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection","volume":"53","author":"Kumada","year":"2018","journal-title":"J Gastroenterol"},{"key":"2025090704215336000_27.e1.e41.37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jvh.13038","article-title":"Glecaprevir\/pibrentasvir in patients with chronic HCV genotype 3 infection: an integrated phase 2\/3 analysis","volume":"26","author":"Flamm","year":"2019","journal-title":"J Viral Hepat"},{"key":"2025090704215336000_27.e1.e41.38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C","volume":"70","author":"D'Ambrosio","year":"2019","journal-title":"J Hepatol"},{"key":"2025090704215336000_27.e1.e41.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.09.018"},{"key":"2025090704215336000_27.e1.e41.40","doi-asserted-by":"crossref","DOI":"10.1186\/s12985-018-1066-8","article-title":"Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study","volume":"15","author":"Tao","year":"2018","journal-title":"Virol J"},{"key":"2025090704215336000_27.e1.e41.41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/liv.13534","article-title":"Sofosbuvir\/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int"},{"key":"2025090704215336000_27.e1.e41.42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200568","article-title":"Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis\/cirrhosis","volume":"13","author":"Mangia","year":"2018","journal-title":"PLoS One"},{"key":"2025090704215336000_27.e1.e41.43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.14423\/SMJ.0000000000000750","article-title":"Measuring adherence to hepatitis C direct-acting antiviral medications: using the VAS in an HCV treatment clinic","volume":"111","author":"Burton","year":"2018","journal-title":"South Med J"},{"key":"2025090704215336000_27.e1.e41.44","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/1060028018766507","article-title":"Incidence of drug interactions identified by clinical pharmacists in veterans initiating treatment for chronic hepatitis C infection","volume":"52","author":"Ottman","year":"2018","journal-title":"Ann Pharmacother"},{"key":"2025090704215336000_27.e1.e41.45","article-title":"PIN3 Sofosbuvir\/velpatasvir vs glecaprevir\/pibrentasvir in genotype 3 hepatitis C virus infected patients","volume":"22","author":"Margusino-Frami\u00f1\u00e1n","year":"2019","journal-title":"Value Health"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2019-002060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T11:22:03Z","timestamp":1757244123000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2019-002060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":45,"journal-issue":{"issue":"e1","published-online":{"date-parts":[[2020,3,26]]},"published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1136\/ejhpharm-2019-002060"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2019-002060","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"type":"print","value":"2047-9956"},{"type":"electronic","value":"2047-9964"}],"subject":[],"published":{"date-parts":[[2020,2,7]]}}}